ObjectiveThe incidence of surgical site infection (SSI) in adolescent idiopathic scoliosis (AIS) patients undergoing surgical correction varies but is commonly reported between 0.5 and 6.7 %. The identification of modifiable risk factors is crucial to preventing these infections in the AIS population. Some potential modifiable risk factors include the use of stainless-steel implants, a larger volume of instrumentation and an increased volume of blood products transfused. However, evidence in support of these factors and others representing true risk for the development of SSI is limited and often varies. We aimed to determine the incidence of SSI in AIS undergoing primary scoliosis fusion at our hospital, and explore demographic and clinical variables in the development of SSI in AIS.MethodsThis was a case control retrospective study. Patients aged 10-19 year-old that underwent posterior spinal fusion for initial correction of AIS at our hospital between the years 2012-2020 were eligible. Patients with any previous spine surgery or spine fracture were excluded. A descriptive analysis was then performed on the data.ResultsOf the 334 patients on which data was collected, one SSI was identified resulting in an incidence of infection of 0.3 %. The largest ethnicity represented was Caucasian with 254 patients. The average age was 14.3 years with averaged follow-up of 6.6 years. The majority of patients (252) received implants composed of titanium and cobalt chrome. The average operation duration was 5 h and 7.7 min, and the average hospital stay was 4.2 days. The average amount of blood loss was 553 ml. Chlorhexidine wipes or some other antimicrobial preparation was used on 197 patients and betadine solution was used on 321.185 patients were recorded to have received either antibiotic-loaded allograft or antibiotic powder and 326 patients were recorded to have received intraoperative antibiotics.ConclusionsThe long term clinical follow up of our study and low incidence of infection provide additional evidence for the benefit of antimicrobial techniques and risk factor mitigation previously suggested in the literature for the prevention of SSI in AIS.Level of evidenceLevel III.

01 Apr 2025·Biomaterials

Aggregation-induced emission-based phototheranostics to combat bacterial infection at wound sites: A review

Review

Author: Li, Yuanyuan ; Zhang, Ming ; Lu, Mengmeng ; Wang, Wentao ; Tang, Ben Zhong ; Xiao, Xiyan ; Zhang, Shixuan ; Fang, Zhurun ; Qian, Yuxin ; Xu, Yan

The healing of chronic wounds infected by bacteria has attracted increasing global concerns. In the past decades, antibiotics have certainly brought hope to cure bacteria-infected chronic wounds. However, the misuse of antibiotics leads to the emergence of numerous multidrug-resistant bacteria, which aggravate the health threat to clinical patients. To address these increasing challenges, scientists are committed to creating novel non-antibiotic strategies to kill bacteria and promote bacteria-infected chronic wound healing. Fortunately, with the quick development of nanotechnology, the representatives of phototherapy, such as photothermal therapy (PTT) and photodynamic therapy (PDT), exhibit promising possibilities in promoting bacteria-infected wound healing. Well-known, photothermal agents and photosensitizers largely determine the effects of PTT and PDT. A common problem for these molecules is the aggregation-induced quenching effect, which highly limits their further applicability in biomedical and clinical fields. Fortunately, the occurrence of aggregation-induced emission luminogens (AIEgens) efficiently overcomes the photobleaching and exhibit advantages, such as strongly aggregated emission, superior photostability, aggregation-enhanced reactive oxygen species (ROS), and heat generation, which makes great sense to the development of PTT and PDT. This article reviews various studies conducted on novel AIEgen-based materials that can mediate potent PDT, PTT, and a combination of PDT and PTT to promote bacteria-infected chronic wound healing.

01 Feb 2025·Talanta

Nanozyme-based colorimetric and smartphone imaging advanced sensing platforms for tetracycline detection and removal in food

Article

Author: Sun, He ; Yang, Yuanzhen ; Zhang, Yang ; Guo, Xinli ; Zhong, Wenbin ; Wang, Guannan ; Wang, Mengmeng

The presence of antibiotic residues poses a significant threat to food assurance, triggering widespread concerns. Therefore, the prompt and accurate detection and removal of antibiotic residues are essential for ensuring food safety. In this study, an aptmer modified triple-metal nanozyme (apt-TMNzyme) sensor was developed, which achieved a portable, visual, intelligent, and fast determination for tetracycline (TET). The proposed apt-TMNzyme exhibited willow leaf-like morphology, high specific surface area and excellent TET adsorption and removal properties. The experiments showed that the apt-TMNzyme had outstanding peroxidase activity and could catalyze the oxidation of 3,3',5,5'-tetramethylbenzidine (TMB) to produce a blue product in the presence of H₂O₂, which provided a visual response signal to TET. This sensor was capable of quantifying TET within a concentration range of 0.2 nM-70 μM, achieving a detection limit of 7.1 nM under optimal conditions. When tested on real food samples, our sensor produced results that closely paralleled those achieved through high-performance liquid chromatography. To improve accessibility and user-friendliness, we also designed a colorimetric testing paper integrated with a smartphone application for intuitive and intelligent detection of TET, which enables the quantitative determination of TET in the concentration range of 0.003-60 μM, the detection limit was 5.1 μM. This integrated portable sensor not only streamlines the testing process, saving time and costs, but also offers a promising solution for rapid and sensitive detection of antibiotic residues.

100 Deals associated with MRSA Antibiotics(Inimmune)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
MRSA - Methicillin resistant Staphylococcus aureus infection	Preclinical	US	Inimmune Corp.Startup	29 Oct 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

MRSA Antibiotics(Inimmune)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation